Processa Pharmaceuticals ($PCSA) Insider Trading & Smart Money Activity
Processa Pharmaceuticals, Inc. ($PCSA) has 12 insider trades on file. In the last 12 months on the open market, 5 insiders bought ($44.74K) and no insider sold, net +$44.74K.
- Insider buyers (12 mo)
- 5
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- +$44.74K
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 0
PCSA insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 9 · $44.74K | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All PCSA insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Justin Yorke | Sell (Option exercise) | 203 sh | +12.9% | +39.2% | Read | |||||
| Insider | James Neal | Buy (Option exercise) | 203 sh | +12.9% | +39.2% | Read | |||||
| Insider | Khoso Baluch | Buy (Option exercise) | 203 sh | +12.9% | +39.2% | Read | |||||
| Insider | David YoungPres. Research & Development | Buy (Open-market buy) | 2.07K sh | $4.59K | -5.9% | +8.1% | — | ||||
| Insider | David YoungPres. Research & Development | Buy (Open-market buy) | 2.07K sh | $4.59K | -5.9% | +8.1% | — | ||||
| Insider | Russell SkibstedChief Financial Officer | Buy (Open-market buy) | 2.65K sh | $5.89K | -5.9% | +8.1% | — | ||||
| Insider | Russell SkibstedChief Financial Officer | Buy (Open-market buy) | 2.65K sh | $5.89K | -5.9% | +8.1% | — | ||||
| Insider | George NgChief Executive Officer | Buy (Open-market buy) | 2.46K sh | $5.47K | -5.9% | +8.1% | — | ||||
| Insider | George NgChief Executive Officer | Buy (Open-market buy) | 2.46K sh | $5.47K | -5.9% | +8.1% | — | ||||
| Insider | Patrick LinChief Business - Strategy Off | Buy (Open-market buy) | 1.83K sh | $4.06K | -5.9% | +8.1% | Read | ||||
| Insider | Patrick LinChief Business - Strategy Off | Buy (Open-market buy) | 1.83K sh | $4.06K | -5.9% | +8.1% | — | ||||
| Insider | Wendy GuyChief Administrative Officer | Buy (Open-market buy) | 2.12K sh | $4.70K | -5.9% | +8.1% | — |
1W / 1M / 6M = how PCSA moved from the trade or filing date.
Insider trading in PCSA: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Justin Yorke | 1 | — | Jun 26, 2026 | ||
| James Neal | 1 | — | Jun 26, 2026 | ||
| Khoso Baluch | 1 | — | Jun 26, 2026 | ||
| David Young | Pres. Research & Development | 2 | +$9.18K | Jun 15, 2026 | |
| Russell Skibsted | Chief Financial Officer | 2 | +$11.78K | Jun 15, 2026 | |
| George Ng | Chief Executive Officer | 2 | +$10.94K | Jun 15, 2026 | |
| Patrick Lin | Chief Business - Strategy Off | 2 | +$8.13K | Jun 15, 2026 | |
| Wendy Guy | Chief Administrative Officer | 1 | +$4.70K | Jun 15, 2026 |
Frequently asked questions
Are PCSA insiders buying or selling?
Over the last 12 months 5 insiders made 9 open-market purchases worth $44.74K and 0 insiders made 0 open-market sales worth $0, a net +$44.74K.
What is the latest insider trade in PCSA?
Justin Yorke filed a sell (option exercise) of 203 sh on Jun 26, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.